



UCB's new CEO Jean-Christophe Tellier introduces executive team

- Since 1 January 2015, CEO Jean-Christophe Tellier has succeeded Roch Doliveux who, as announced several months ago, stepped down on 31 December 2014
- With effect 1 February 2015, UCB's Executive Committee team welcomes three new members to drive growth and provide more focused value for patients living with severe diseases

Brussels – January 13, 2015 – 7:00 am CET: Jean-Christophe Tellier has taken up the role as CEO of UCB on 1 January 2015, succeeding Roch Doliveux. He is also Chairman of UCB's Executive Committee and member of the Board of Directors.

Roch Doliveux stepped down on 31 December 2014 after successfully leading UCB for the last 10 years. UCB's Board of Directors granted him the titles of Honorary Member of the Board and Honorary Chairman of the Executive Committee.

Jean-Christophe Tellier joined the company in 2011 and was instrumental in establishing the company's current strategy; he has played a key role in driving the growth of UCB's three core medicines, Cimzia[®], Vimpat[®] and Neupro[®].

With a distinguished 25-year career in the biopharmaceutical industry, Jean Christophe Tellier comes with significant expertise and career achievements, a highly developed patient-focused approach, a medical background as a rheumatologist and a passion for developing talent.

To fulfill the company's mission Jean-Christophe Tellier will enjoy the support of a strong Executive Committee with new members joining the existing team.

Commenting on the composition of UCB's leadership team, Jean-Christophe Tellier explains: *"UCB's leadership team has done a tremendous job in transforming the company into a global science leader helping patients with severe diseases enjoy more normal lives. It is important for UCB to ensure leadership continuity while adding expertise in our focus areas of neurology and immunology to accelerate momentum as we head into our next period of growth."*

UCB's leadership team, effective 1 February 2015, will have a clear focus on key disease or domain expertise areas. UCB's Executive Committee will be structured as follows, each unit being led by an

Executive Vice President reporting to [Jean-Christophe Tellier](#), Chief Executive Officer and Chairman of the Executive Committee.

Patient Value Units:

- New Medicines : [Ismail Kola](#), New Medicines Head and Chief Scientific Officer
- Neurology : [Jeff Wren](#), Patient Value Unit Head, previously head of UCB's North American region
- Immunology : [Emmanuel Caeymaex](#), Patient Value Unit Head, previously head of UCB's Cimzia® team
- Bone disorders : this position is still to be filled and will be led ad interim by [Iris Loew Friedrich](#)

Patient Value Practices :

- Strategic Marketing : [Bharat Tewarie](#), Chief Marketing Officer. A physician with strong industry experience, he joins UCB from Merck-Serono where he was Senior Vice President, head of Global Business Franchise Neurology & Immunology and head of Global Business Franchise Medical Devices
- Development and Medical: [Iris Loew Friedrich](#), Chief Medical Officer

Patient Value Operations:

- Geographic Operations, Established Brands, Technical Operations and Business Development: [Mark McDade](#), Chief Operating Officer

Patient Value Functions:

- Finance: [Detlef Thielgen](#), Chief Financial Officer
- Talent and Company Reputation: [Fabrice Enderlin](#), Chief Talent Officer
- Legal: [Anna Richo](#), General Counsel

Full biographies of UCB's Executive Committee members are available on <http://www.ucb.com/investors/Governance/Corporate-governance>

For further information –

Corporate Communications

France Nivelles, Global Communications, UCB
T +32.2.559.9178, france.nivelles@ucb.com

Laurent Schots,
Media Relations, UCB T+32.2.559.92.64,
Laurent.schots@ucb.com

Investor Relations

Antje Witte, Investor Relations, UCB
T +32.2.559.94.14,
antje.witte@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of €3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.